

# Keith M Sullivan

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3056055/publications.pdf>

Version: 2024-02-01

66  
papers

3,007  
citations

236925

25  
h-index

161849

54  
g-index

67  
all docs

67  
docs citations

67  
times ranked

3160  
citing authors

#	ARTICLE	IF	CITATIONS
1	Bone Marrow Transplantation for Sickle Cell Disease. <i>New England Journal of Medicine</i> , 1996, 335, 369-376.	27.0	545
2	Myeloablative Autologous Stem-Cell Transplantation for Severe Scleroderma. <i>New England Journal of Medicine</i> , 2018, 378, 35-47.	27.0	417
3	High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for severe systemic sclerosis: long-term follow-up of the US multicenter pilot study. <i>Blood</i> , 2007, 110, 1388-1396.	1.4	240
4	High-dose immunosuppressive therapy for severe systemic sclerosis: initial outcomes. <i>Blood</i> , 2002, 100, 1602-1610.	1.4	161
5	A phase 1/2 study of an adjuvanted varicella-zoster virus subunit vaccine in autologous hematopoietic cell transplant recipients. <i>Blood</i> , 2014, 124, 2921-2929.	1.4	145
6	Effect of Recombinant Zoster Vaccine on Incidence of Herpes Zoster After Autologous Stem Cell Transplantation. <i>JAMA - Journal of the American Medical Association</i> , 2019, 322, 123.	7.4	143
7	Short-term progression of interstitial lung disease in systemic sclerosis predicts long-term survival in two independent clinical trial cohorts. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 122-130.	0.9	141
8	Indications and Results of HLA-Identical Sibling Hematopoietic Cell Transplantation for Sickle Cell Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 207-211.	2.0	97
9	Hematopoietic Cell Transplantation for Autoimmune Disease: Updates from Europe and the United States. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, S48-S56.	2.0	77
10	How I treat refractory chronic graft-versus-host disease. <i>Blood</i> , 2019, 133, 1191-1200.	1.4	70
11	Autologous Hematopoietic Cell Transplantation for Treatment-Refractory Relapsing Multiple Sclerosis: Position Statement from the American Society for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 845-854.	2.0	69
12	Gastric Antral Vascular Ectasia and Its Clinical Correlates in Patients with Early Diffuse Systemic Sclerosis in the SCOT Trial. <i>Journal of Rheumatology</i> , 2013, 40, 455-460.	2.0	67
13	Universal Mask Usage for Reduction of Respiratory Viral Infections After Stem Cell Transplant: A Prospective Trial. <i>Clinical Infectious Diseases</i> , 2016, 63, 999-1006.	5.8	63
14	Transplantation for Autoimmune Diseases in North and South America: A Report of the Center for International Blood and Marrow Transplant Research. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 1471-1478.	2.0	62
15	High-dose immunosuppressive therapy for severe systemic sclerosis: initial outcomes. <i>Blood</i> , 2002, 100, 1602-10.	1.4	61
16	Recovery from and consequences of severe iatrogenic lymphopenia (induced to treat autoimmune) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 56	3.2	56
17	Bone marrow transplantation for adolescents and young adults with sickle cell disease: Results of a prospective multicenter pilot study. <i>American Journal of Hematology</i> , 2019, 94, 446-454.	4.1	56
18	Systemic Sclerosis as an Indication for Autologous Hematopoietic Cell Transplantation: Position Statement from the American Society for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1961-1964.	2.0	47

#	ARTICLE	IF	CITATIONS
19	Clinical risks and healthcare utilization of hematopoietic cell transplantation for sickle cell disease in the USA using merged databases. <i>Haematologica</i> , 2017, 102, 1823-1832.	3.5	43
20	Myeloablation followed by autologous stem cell transplantation normalises systemic sclerosis molecular signatures. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1371-1378.	0.9	43
21	An mHealth Pain Coping Skills Training Intervention for Hematopoietic Stem Cell Transplantation Patients: Development and Pilot Randomized Controlled Trial. <i>JMIR MHealth and UHealth</i> , 2018, 6, e66.	3.7	31
22	Recombinant Zoster Vaccine Significantly Reduces the Impact on Quality of Life Caused by Herpes Zoster in Adult Autologous Hematopoietic Stem Cell Transplant Recipients: A Randomized Placebo-Controlled Trial (ZOE-HSCT). <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 2474-2481.	2.0	30
23	Machine learning predicts stem cell transplant response in severe scleroderma. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1608-1615.	0.9	29
24	Carbon Monoxide Diffusion Capacity: How Low Can You Go for Hematopoietic Cell Transplantation Eligibility?. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 447-453.	2.0	27
25	Renal Shielding and Dosimetry for Patients With Severe Systemic Sclerosis Receiving Immunoablation With Total Body Irradiation in the Scleroderma: Cyclophosphamide or Transplantation Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 79, 1248-1255.	0.8	27
26	Review: Hematopoietic Stem Cell Transplantation for Scleroderma: Effective Immunomodulatory Therapy for Patients With Pulmonary Involvement. <i>Arthritis and Rheumatology</i> , 2016, 68, 2361-2371.	5.6	27
27	Acute Kidney Injury in Patients with Systemic Sclerosis Participating in Hematopoietic Cell Transplantation Trials in the United States. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 674-681.	2.0	21
28	Plerixafor (a CXCR4 antagonist) following myeloablative allogeneic hematopoietic stem cell transplantation enhances hematopoietic recovery. <i>Journal of Hematology and Oncology</i> , 2016, 9, 71.	17.0	20
29	Autologous Stem-Cell Transplantation for Severe Scleroderma. <i>New England Journal of Medicine</i> , 2018, 378, 1066-1067.	27.0	17
30	Adjuvanted recombinant zoster vaccine in adult autologous stem cell transplant recipients: polyfunctional immune responses and lessons for clinical practice. <i>Human Vaccines and Immunotherapeutics</i> , 2021, 17, 4144-4154.	3.3	16
31	Reduced-Intensity Allogeneic Transplantation Using Alemtuzumab from HLA-Matched Related, Unrelated, or Haploidentical Related Donors for Patients with Hematologic Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 257-263.	2.0	15
32	Phase I dose escalation study of naive T-cell depleted donor lymphocyte infusion following allogeneic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2021, 56, 137-143.	2.4	15
33	Application of stem cell transplantation in autoimmune diseases. <i>Current Opinion in Hematology</i> , 2019, 26, 392-398.	2.5	12
34	Large-scale Characterization of Systemic Sclerosis Serum Protein Profile: Comparison to Peripheral Blood Cell Transcriptome and Correlations With Skin/Lung Fibrosis. <i>Arthritis and Rheumatology</i> , 2021, 73, 660-670.	5.6	10
35	Quantifying Skin Stiffness in Graft-Versus-Host Disease, Morphea, and Systemic Sclerosis Using Acoustic Radiation Force Impulse Imaging and Shear Wave Elastography. <i>Journal of Investigative Dermatology</i> , 2021, 141, 924-927.e2.	0.7	10
36	Shared Decision-Making in Hematopoietic Stem Cell Transplantation for Sickle Cell Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 883-884.	2.0	9

#	ARTICLE	IF	CITATIONS
37	Impact of High Dose Cyclophosphamide on the Outcome of Autologous Stem Cell Transplant in Patients with Newly Diagnosed Multiple Myeloma,. Blood, 2011, 118, 4127-4127.	1.4	9
38	Manufacture of Autologous CD34+ Selected Grafts in the NIAID-Sponsored HALT-MS and SCOT Multicenter Clinical Trials for Autoimmune Diseases. Biology of Blood and Marrow Transplantation, 2017, 23, 1463-1472.	2.0	8
39	Lymphocyte subset abnormalities in early severe scleroderma favor a Th2 phenotype and are not altered by prior immunosuppressive therapy. Rheumatology, 2022, 61, 4155-4162.	1.9	8
40	Hematopoietic Cell Transplantation for Sickle Cell Disease: Updated Results of the Multicenter Trial.. Blood, 2004, 104, 104-104.	1.4	7
41	Haemopoietic stem-cell transplantation for systemic sclerosis. Lancet, The, 2012, 379, 219.	13.7	6
42	Use of the National Institutes of Health Consensus Guidelines Improves the Diagnostic Sensitivity of Gastrointestinal Graft-Versus-Host Disease. Archives of Pathology and Laboratory Medicine, 2018, 142, 1098-1105.	2.5	6
43	Allogeneic HSCT for autoimmune disease: a shared decision. Nature Reviews Rheumatology, 2019, 15, 701-702.	8.0	6
44	Interrater Reliability of Clinical Grading Measures for Cutaneous Chronic Graft-vs-Host Disease. JAMA Dermatology, 2019, 155, 833.	4.1	6
45	Efficacy and safety of high-dose chemotherapy with autologous stem cell transplantation in senior versus younger adults with newly diagnosed multiple myeloma. Hematological Oncology, 2017, 35, 752-759.	1.7	5
46	Partially HLA Matched, Non-Myeloablative Allogeneic Transplantation.. Blood, 2005, 106, 2896-2896.	1.4	5
47	Bone marrow transplantation for non-malignant disease. International Journal of Hematology, 2002, 76, 169-170.	1.6	4
48	Safety and efficacy of HSCT for systemic sclerosis across clinical trials. Nature Reviews Rheumatology, 2020, 16, 661-661.	8.0	4
49	Cross-trial comparisons in reviews: proceed with caution. Nature Reviews Rheumatology, 2020, 16, 663-664.	8.0	4
50	Clinical and Molecular Findings after Autologous Stem Cell Transplantation or Cyclophosphamide for Scleroderma: Handling Missing Longitudinal Data. Arthritis Care and Research, 2021, , .	3.4	3
51	Country-Level Macroeconomic Indicators Predict Early Post-Allogeneic Hematopoietic Cell Transplantation Survival in Acute Lymphoblastic Leukemia: A CIBMTR Analysis. Biology of Blood and Marrow Transplantation, 2018, 24, 1928-1935.	2.0	2
52	Cognitive impairment in candidates for allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplantation, 2021, , .	2.4	2
53	Adult Umbilical Cord Blood Transplantation Following Non-Myeloablative Conditioning; Impact of Increased Cell Dose and 200cGy TBI on Engraftment and Survival.. Blood, 2006, 108, 5399-5399.	1.4	1
54	High Dose BCNU/Melphalan Preparative Regimen Doubles Event Free Survival of Myeloma Patients Undergoing Autologous Transplantation. Blood, 2011, 118, 2012-2012.	1.4	1

#	ARTICLE	IF	CITATIONS
55	Myeloablative Intravenous Busulfan/Fludarabine Conditioning Does Not Facilitate Reliable Engraftment of Dual Umbilical Cord Blood Grafts in Adult Recipients.. Blood, 2007, 110, 2007-2007.	1.4	1
56	Clinical and Neuroimaging Correlates of Post-Transplant Delirium. Biology of Blood and Marrow Transplantation, 2020, 26, 2323-2328.	2.0	0
57	Total Body Irradiation 1350cGy/Fludarabine (TBI/FLU) vs Myeloablative Busulfan/Fludarabine (Bu/Flu) Preparation in Adult Recipients of Dual Umbilical Cord Blood (UCB) Transplantation: Superior Engraftment with Low Treatment-Related Mortality. Blood, 2008, 112, 4403-4403.	1.4	0
58	Bortezomib Plus Melphalan and Prednisone as Induction Prior to Transplant or as Frontline Therapy for Non-Transplant Candidates in Patients with Previously Untreated Multiple Myeloma.. Blood, 2008, 112, 3325-3325.	1.4	0
59	Early Pre/Post Fluoro-Deoxyglucose Positive Emission Tomography (PET) Does Not Predict Outcome of Patients Undergoing Hematopoietic Stem Cell Transplantation in Hodgkins Disease and Non-Hodgkins Lymphoma.. Blood, 2008, 112, 2180-2180.	1.4	0
60	Adult Dual Umbilical Cord Blood Transplantation Using Myeloablative Total Body Irradiation (1350cGy) and Fludarabine Conditioning. Blood, 2010, 116, 3523-3523.	1.4	0
61	Prospective, Biological Randomized Study of T-Cell Depleted Nonmyeloablative Allogeneic Transplantation From HLA-Matched Related, Unrelated or Haploidentical Donors for Patients with Hematologic Malignancies. Blood, 2010, 116, 3541-3541.	1.4	0
62	The Impact of Lymphocyte Subset Recovery At 3 Months on Progression-Free Survival After Myeloablative Allogeneic Stem Cell Transplantation,. Blood, 2011, 118, 4065-4065.	1.4	0
63	Pre-Transplant Hepatic Steatosis (fatty liver) Predicts Chronic Graft-Vs-Host Disease but Does Not Affect Mortality. Blood, 2019, 134, 5731-5731.	1.4	0
64	A Phase II Trial to Compare Allogeneic Transplant Vs. Standard of Care for Severe Sickle Cell Disease: Blood and Marrow Transplant Clinical Trials Network (BMT CTN) Protocol 1503. Blood, 2019, 134, 4592-4592.	1.4	0
65	7. Can Recombinant Zoster Vaccine Administration Decrease the Use of Herpes Zoster-related Pain Medication Across Randomized Controlled Studies?. Open Forum Infectious Diseases, 2020, 7, S3-S4.	0.9	0
66	EPR22-118: Incidence of Herpes Zoster in Immunocompromised Individuals and Zoster Vaccination as an Effective Preventative Strategy. Journal of the National Comprehensive Cancer Network: JNCCN, 2022, 20, EPR22-118.	4.9	0